Please login to the form below

Not currently logged in
Email:
Password:

SCLC

This page shows the latest SCLC news and features for those working in and with pharma, biotech and healthcare.

Nektar confirms BMS deal for NKTR-214 is on track

Nektar confirms BMS deal for NKTR-214 is on track

Robin said that studies are now underway or planned for the CD122-biased agonist in small cell lung cancer (SCLC), breast cancer, colorectal cancer, gastric cancer, triple-negative breast cancer (TNBC)

Latest news

More from news
Approximately 2 fully matching, plus 15 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2017 Deal Watch February 2017

    triple-negative breast cancer (TNBC), small-cell lung cancer (SCLC), non-small-cell lung cancer (NSCLC) and pancreatic cancer.  .

  • Deal Watch April 2016 Deal Watch April 2016

    Rova-T showed a 44% overall response rate in DLL-expressing small cell lung cancer (SCLC) patients who had failed one or more standard therapies.

  • Deal Watch November 2015 Deal Watch November 2015

    July finalised a $730m exclusive deal with Boehringer Ingelheim for HM61713, an orally active third generation EGFR agent in small cell lung cancer (SCLC).

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics